News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Sets Johnson & Johnson (JNJ)'s TB Drug on Accelerated Path to Approval


9/6/2012 7:34:51 AM

Johnson & Johnson said the U.S. Food and Drug Administration will give a priority review to its experimental treatment for multidrug-resistant tuberculosis. J&J's Janssen Research & Development unit on June 29 applied for approval to market bedaquiline, or TMC207, as part of combination therapy for adults with multidrug-resistant tuberculosis lung infections. Under a priority review, the FDA aims to decide whether to approve drugs within six months of the application's submission, rather than the standard 10 months, because they may offer a major advance or treat a condition with few or no therapies. Bedaquiline would be the first drug specifically for multidrug-resistant tuberculosis, and the first new type of TB drug in more than four decades.

Read at nj.com
Read at Nasdaq
Read at Market Watch
Read at USA Today
Read at News-Medical


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES